Search company, investor...
Search
CureVac company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

curevac.com

Founded Year

2000

Stage

IPO | IPO

Total Raised

$1.281B

Date of IPO

8/14/2020

Market Cap

1.68B

Stock Price

7.69

About CureVac

CureVac, a German clinical stage biopharmaceutical company, serves the field of mRNA-based technology platforms for medical purposes, in which unmodified mRNA is specifically optimized and formulated. CureVac has been developing mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive. Moreover, CureVac's technology RNArt is designed as a molecular therapy to trigger the body's own production of therapeutic proteins without stimulating the immune system.

CureVac Headquarters Location

Friedrich-Miescher-Str. 15

Tubingen, 72076,

Germany

+49 7071 9883 - 0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing CureVac

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned CureVac in 5 CB Insights research briefs, most recently on Jul 6, 2022.

Expert Collections containing CureVac

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CureVac is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CureVac Patents

CureVac has filed 266 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Vaccines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/17/2020

9/20/2022

Molecular biology, Biotechnology, RNA, DNA, Genetics

Grant

Application Date

8/17/2020

Grant Date

9/20/2022

Title

Related Topics

Molecular biology, Biotechnology, RNA, DNA, Genetics

Status

Grant

Latest CureVac News

FACTBOX-Latest on the worldwide spread of the coronavirus

Sep 5, 2022

* Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac's European patents, according to a regulatory filing on Friday. ASIA-PACIFIC * Taiwan will resume visa free entry for visitors from countries including the United States and Canada from next week, the government said, as it continues to ease COVID-19 controls. * Chinese President Xi Jinping will visit Kazakhstan on Sept. Reuters | Updated: 05-09-2022 20:27 IST | Created: 05-09-2022 20:27 IST SHARE China's Shenzhen city eased a COVID-19 lockdown as infections in its latest outbreak showed signs of stabilising, while most of the 21.2 million residents of Chengdu city faced extended curbs on their movements. DEATHS AND INFECTIONS * Eikon users, click on COVID-19: MacroVitals for a case tracker and summary of news. cpurl://apps.cp./cms/?navid=1592404098 EUROPE * The European Union's drugs regulator may be a few weeks from a decision to approve the experimental COVID-19 vaccine developed by France's Sanofi and its British partner GSK, a Sanofi executive said. * Britain said on Saturday it had added a Pfizer vaccine to its COVID-19 booster shot programme for the coming months. * EU countries should start offering COVID boosters to their populations now to contain a new wave of infections expected this autumn and winter, the bloc's executive said in a document seen by Reuters on Friday ahead of its official release. AMERICAS * U.S. President Joe Biden will request $22.4 billion for COVID-19 relief ahead of a potential fall case surge, the White House said on Friday. * Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales , seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac's European patents, according to a regulatory filing on Friday. ASIA-PACIFIC * Taiwan will resume visa free entry for visitors from countries including the United States and Canada from next week, the government said, as it continues to ease COVID-19 controls. * Chinese President Xi Jinping will visit Kazakhstan on Sept. 14, the Kazakh Foreign Ministry said, in what would be his first foreign trip since the beginning of the pandemic. * China's CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster. AFRICA AND MIDDLE EAST * El Al Israel Airlines will resume non-stop flights to Hong Kong in February after halting them at the outset of the pandemic in 2020. ECONOMIC IMPACT * China's blue-chip stocks closed lower on Monday, led by consumer staples amid tightening COVID-19 curbs in some big cities, while the yuan ended the domestic trading session at a more than two-year low against the dollar. * A strong rebound in China's services sector eased slightly in August amid fresh COVID-19 flare-ups but business confidence rose to a nine-month high, a private survey showed. (Compiled by Olivier Sorgho and Valentine Baldassari; Edited by Ed Osmond) (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) READ MORE ON:

CureVac Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CureVac Rank

  • When was CureVac founded?

    CureVac was founded in 2000.

  • Where is CureVac's headquarters?

    CureVac's headquarters is located at Friedrich-Miescher-Str. 15, Tubingen.

  • What is CureVac's latest funding round?

    CureVac's latest funding round is IPO.

  • How much did CureVac raise?

    CureVac raised a total of $1.281B.

  • Who are the investors of CureVac?

    Investors of CureVac include GSK, Qatar Investment Authority, European Investment Bank, KfW, European Commission and 14 more.

  • Who are CureVac's competitors?

    Competitors of CureVac include Ethris.

You May Also Like

Recode Therapeutics Logo
Recode Therapeutics

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.

Ethris Logo
Ethris

Ethris is paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. Ethris is advancing transcript therapies to transform the treatment of disease.

BioNTech Logo
BioNTech

BioNTech is developing personalized immunotherapies to help the treatment of people with cancer and other debilitating diseases.

Moderna Therapeutics Logo
Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

A
Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: ARCT) focuseS on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.